European Journal of Molecular & Clinical Medicine

ISSN 2515-8260 Volume 07, Issue 07, 2020

A REVIEW OF THERAPEUTIC TREATMENT DURING COVID-19

Dr.Lokeshwari V Assistant Professor[1],

Dr. Shanmuga Priyan S Associate Professor[2]

Meenakshi Academy of Higher Education and Research

lokeshwariv@mmchri.ac.in

Abstract:

In the world, the third big coronavirus (CoV) outbreak originated in late 2019 and is called COVID-19 in Wuhan, Hubei, China [1]. The epidemic first spread to nearby Asian countries and then across the world after an initial explosive outbreak of pneumonia of uncertain aetiology in China. The bilateral lung glassy opacity of patients with COVID-19 was found to have a constellation of symptoms such as flu, dry cough, dyspnea, sore throat, and nasal inflammation and radiological findings. vitamin D is subject to a range of ways, including physical barriers, cellular natural immunity and adaptive immunity, to lower risk of microbial infection and death. The supplementation with vitamin D has shown beneficial effects in viral influenza, including HIV infections. During Covid 19, the effects of vitamin D supplementation remain controversial. In order to help identify cut offs for vitamin D and, last but not least, which dose is the strongest, clinical trials are needed.

Keywords: COVID-19, Therapeutic treatment, Systematic Review

BACKGROUND

The risk of multiple non-pulmonary complications such as acute myocardial damage, kidney dysfunction and thromboembolic events is raised by coronavirus disease 2019 (COVID-19). The nature of deep endothelial dysfunction and injury can be a potential unified cause for these phenomena. This study offers a description of the relationship and the therapeutical effects of endothelial dysfunction with COVID-19 [2,3]. The primary comorbidities that raise susceptibility of extreme COVID-19 such as elevated blood pressure, obesity, diabetes mellitus, coronary-arters or heart disease are typical for endothellial dysfunction. Preliminary studies have indicated that endothelial vascular cells can be compromised by serious

ISSN 2515-8260 Volume 07, Issue 07, 2020

Coronavirus 2 (SARS-CoV-2) acute respiratory syndrome and in advanced COVID-19 circumstances evidence of broad endothelitis and inflammation is present. The critical role of endothelial cells in the maintenance and control of vascular homoostasis and blood coagulation has been identified previously. A worsening endothelial dysfunction in COVID-19 can thus impair organs and result in both macro and microvascular thrombotic events. Inhibitors of the angiotensin transporter (ACE), the blocker of angiotensin receptors (RBs), statins and the endothelial dysfunction are considered to boost. Data from smaller observer trials and other viral infections show that the COVID-19 is beneficial[4–6]. Other therapies under review for COVID-19 can also enhance the dysfunction of endothelial patients. Treatment in COVID-19 may be beneficial for the prevention and enhancement of endothelial disfunction. This principle is currently being tested in many clinical trials. Preliminary findings suggest that patients with cardiovascular risk factors and/or cardiovascular disease are more at risk of hospitalisation and the initiation of a more serious disease path with COVID-19. These risk factors cover elderly age, elevated blood pressure, obesity, diabetes mellitus, chronic lung disease, pulmonary disease and coronary artery diseases [7].

EFFECTS OF COVID

It is noteworthy that endothelial dysfunction is a common denominator in all such cardiometabolic diseases. Vasoconstration, inflammation, permeability and coagulation are associated with dysfunction. The endothel is necessary for retaining vascular tones and homosexuality. It is correlated with core risk factors, such as age, hypertension, diabetes and obesity, and cardiovascular disease growth and progression [8]. Classically, the dilation of brachial or hormone arteries to the reaction of shear stress or external stimulus is determined by endothelic function. New methods often allow smaller vascular beds including retinal microcirculation to be evaluations. A big coronavirus disease outbreak (CoV) is currently emerging globally. In Wuhan, Hubei, China, the new CoV disease began in late 2019[9]. The World Health Organization (WHO) named the COVID-19 outbreak on 11 February 2020. The first CoV infection outbreak in China also started in 2002 with extreme acute respiratory syndrome (SARS) coV in its clinical characteristics and a further epidemic, currently in progress in the Middle East, was first identified in 2012 with the names Middle East Respiratory Syndrome (MERS)-CoV. The COVID-19 epidemic is the third that spreads around the glove, with many nations, such as the United States, Italy, Spain, China, Germany and Iran leading in the widely reported cases and associated fatals, beginning with the

ISSN 2515-8260 Volume 07, Issue 07, 2020

explosive outbreak in China alone and subsequently in neighbouring Asian countries[10]. Tests obtained from the throat and nasal swabs are valuable for an examination of the polymerase chain reaction (PCR) that detects a SARS-CoV-2 infection. The major signs of COVID-19 are fever (85%), and 45% of the cases early include febrile, dyspnea, dry cough, sore throat, nasal inflammation, and radiological results of bilateral glassy pulmonary opacity[11]. Harm to the lungs can lead to a septic shortage of acute respiratory distress syndrome (ARDS). These are the two primary causes of COVID-19 hospitalisation and death in an intensive care unit (ICU) in patients over 60 years of age. Several other symptoms are observed, such as bone and muscle aches, chills and headaches. Nausea or vomiting and diarrhoea are the least reported symptoms, respectively in 5% and 3,7% of cases. Moreover, in COVID-19 cases, anosmia and ageusia tend to be typical clinical characteristics. Several studies indicate that the community of smokers appears to have a higher density of angiotensin-converting enzyme 2 (ACE2) receptors, especially at an earlier age [12–14]. COVID-19 has a period of incubation of roughly 2–14 days, with a global mean of three days and a fatality risk of 12% (CFR). The proposed self-quarantine cut-off is 14 days. COVID-19 subjects exhibit diminished, or normal, leucocytes and lymphocytopenia, as well as systematic elevations in the pyrogenic cytokines interleukin-6, IL-10 and TNF-alle [7, 10]. In vital conditions, some studies found an increase in neutrophilia, elevated D-dimer, urea nitrogen (BUN) and creatinine in blood plasma. There have also been records of an elevated plasma level of IL-2,IL-7,IL-10, colony-stimulating agent in the granulocyte, 10 kD, interferon (IFN)-α-induced protein-10, monocyte protein protein-1 and macrophage inflammatory protein 1-α. Early diagnosis, insulation and medication are necessary to treat and manage the disease. Early diagnosis Serum antibody identification of infected patient, particularly in patients with negative nucleic acid tests, is of great importance in diagnosing them. Concurrent identification of both IgM and IgG anticuerpos helps recognise the infection level. The COVID-19 antibody profile typically displays a standard profile of IgM and IgG patterns. IgM antibodies for SARS appear approximately two weeks after infection, and vanish at the end of week 12, whereas IgG antibodies can survive for months, or even years. The longitudinal distribution of antibodies for COVID-19 however appears to be uncertain [14–16].

VITAMIN D

Vitamin D helps decrease the risk of microbial infections and mortality, primarily affecting three types of activities: physical barriers, normal cellular immunity and adaptive immunity. Vitamin D strengthens revolutionary cellular immunity, in part through the activation of

ISSN 2515-8260 Volume 07, Issue 07, 2020

antimicrobial peptides, including human cathelicidin LL-37 and 1,25-dihdroxyvitamin D and defensins, while retaining close intersections, gap intersections and bonds [17–19]. The effects of cathelicidins, which have a direct antimicrobial activity against a wide variety of bacteria, should be observed, in particular. This contains, inter alia, bacteria that are Gram-positive and Gram-negative, viruses which are enclosed or not and fungi. Cathelicidin demonstrates more roles, including the secretion into the infection site of a number of inflammatory cytokines, the activation and clearance of chemotaxis of the neutrophils, monocytes, macrophages, or T lymphocytes, and apoptosis and autophagy caused by infected epithelial cells [20,21].

RESPIRATORY FAILURE

Severe coronavirus acute breathing syndrome 2, as its name indicates, was initially deemed to cause only respiratory failure. Several studies of ischemic stroke patients in coronavirus disease 2019 (COVID–19) have, however, been released [22–25]. The pathways used to produce SARS-CoV-2 blood clots and large vessel strokes must be identified as they have therapeutic repercussions. SARS-CoV-2 penetrates the bloodstream from the lung capillary adjacent to the alveolus by shattering the blood–air barrier and then binds to endothelial cells the angiotensin-converting enzyme-II receptors. Once SARS-CoV-2 is entered in the bloodstream, a cascade (stages 1-8) occurs, including the build up of angiotensin II, reactive oxygen species, endothelial dysfunction, beta 2-glycoprotein oxidation, 1, the development of platlet aggregation compounds, the formation of coagulation cascades or cross-linked blood clots, which contribute to pulmonary emboli (PT) and pulmonary embolism (PE) The proof appears that COVID-19 is a blood clotting disease and SARS-CoV-2 is used to enter the blood stream via the respiratory pathway. Different degrees of collateral damage arise when blood-air barrier bursts. Although the role of blood dilutants in blood clotting and blood management in Covid-19 must be assessed, while antiviral and immune therapies are being investigated. In addition to blood diluents, the emergent treatment of life-threatening clots like PE and large-vessel strokes must take into consideration the use of permanent aspiration and clot recovery devices (approved in Europe, cleared in the United States) or cyclical suction devices [26–29].

DISCUSSION

In order to end this pandemic, several tactics are required. Some of these actions include personal protective devices for all health personnel, reorganise health care facilities with

ISSN 2515-8260 Volume 07, Issue 07, 2020

COVID 19 specialised high-dependence clinics / hospitals, research new therapies and vaccines and allow people to keep their wellbeing apart even though the pandemic recedes [30–32].

In the absence of long-term SARS-CoV-2 immunisation or successful COVID-19 treatment, health practitioners need to have access to clear details reliably predicting which virus patients will experience clinical degradation of COVID-19 (high-risk populations) [33,34]. For successful clinical evaluation, risk stratification, capital repositioning and tailored public-health response, improved clinical definition of people that are at risk for serious disease with COVID-19 [35–37].

There have also been clear predictors of serious illness risk: co-morbidity, age, breathlessness and lymphopenia. Several predictors have been explicitly defined. Many other COVID-19 predictors contributing to clinical severity were suggested, but their validity was disputed. Due to incredibly demanding conditions in wards/iCUs with overwork and working in persistence of emergency, it is not shocking how complex the identification of forecasting data is when anamnestic and behaviour data may have been obtained inaccurately [38,39]. Intuitively, tobacco smoking is believed to be one vulnerable to extreme COVID-19 illness, as a risk of significant air infections is considered to be increasing. Is that real, however? On this subject, researchers discuss the hypothesis that smokers are more at-risk and that unpredictably results suggest that smocking may potentially have a preventive impact. This is the opposite and contra-intuitive inference. Their systematic analysis concluded that smoking is extremely healthy for the COVID-19 hospital based on a remarkably low smoking rate for COVID-19 patients [40].

REFERENCES:

1. Arya R, Kumari S, Pandey B, et al. Structural insights into SARS-CoV-2 proteins. *J Mol Biol*. 2021;433(2). doi:10.1016/j.jmb.2020.11.024

2. Bhattacharya R, Gupta AM, Mitra S, Mandal S, Biswas SR. A natural food preservative peptide nisin can interact with the SARS-CoV-2 spike protein receptor human ACE2. *Virology*. 2021;552:107-111. doi:10.1016/j.virol.2020.10.002

3. Grassin-Delyle S, Roquencourt C, Moine P, et al. Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study. *EBioMedicine*. 2021;63.

doi:10.1016/j.ebiom.2020.103154

4. Kalicińska E, Szymczak D, Andrasiak I, et al. Lymphocyte subsets in haematological patients with COVID-19: Multicentre prospective study. *Transl Oncol*. 2021;14(1). doi:10.1016/j.tranon.2020.100943

5. Lopes D V, Lazar Neto F, Marques LC, Lima RBO, Brandão AAGS. Methemoglobinemia and hemolytic anemia after COVID-19 infection without identifiable eliciting drug: A case-report. *IDCases*. 2021;23. doi:10.1016/j.idcr.2020.e01013

6. Marian AJ. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. *Cardiovasc Pathol*. 2021;50. doi:10.1016/j.carpath.2020.107278

7. Wu J, Yu J, Shi X, et al. Epidemiological and clinical characteristics of 70 cases of coronavirus disease and concomitant hepatitis B virus infection: A multicentre descriptive study. *J Viral Hepat*. 2021;28(1):80-88. doi:10.1111/jvh.13404

8. Lee J-H, Choi M, Jung Y, et al. A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2). *Biosens Bioelectron*. 2021;171. doi:10.1016/j.bios.2020.112715

9. Salah M, Belghiti ME, Aitouna AO, et al. MEDT study of the 1,3-DC reaction of diazomethane with Psilostachyin and investigation about the interactions of some pyrazoline derivatives with protease (Mpro) of nCoV-2. *J Mol Graph Model*. 2021;102. doi:10.1016/j.jmgm.2020.107763

10. Proud PC, Tsitoura D, Watson RJ, et al. Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. *EBioMedicine*. 2021;63. doi:10.1016/j.ebiom.2020.103153

11. Garg M, Sharma AL, Singh S. Advancement in biosensors for inflammatory biomarkers of SARS-CoV-2 during 2019–2020. *Biosens Bioelectron*. 2021;171. doi:10.1016/j.bios.2020.112703

12. DeLeo PC, Huynh C, Pattanayek M, Schmid KC, Pechacek N. Assessment of ecological hazards and environmental fate of disinfectant quaternary ammonium compounds. *Ecotoxicol Environ Saf*. 2020;206. doi:10.1016/j.ecoenv.2020.111116

13. Mortaz E, Malkmohammad M, Jamaati H, et al. Silent hypoxia: higher NO in red blood cells of COVID-19 patients. *BMC Pulm Med*. 2020;20(1). doi:10.1186/s12890-020-01310-8

14. Mukherjee R. Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus. *J Biosci*. 2020;45(1). doi:10.1007/s12038-020-00040-7

15. Singh D, Wasan H, Reeta KH. Heme oxygenase-1 modulation: A potential therapeutic target for COVID-19 and associated complications. *Free Radic Biol Med*. 2020;161:263-271. doi:10.1016/j.freeradbiomed.2020.10.016

16. Frix A, Schoneveld L, Ladang A, et al. Could KL-6 levels in COVID-19 help to predict lung disease? *Respir Res*. 2020;21(1). doi:10.1186/s12931-020-01560-4

17. Brizola E, Adami G, Baroncelli GI, et al. Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemic. *Orphanet J Rare Dis*. 2020;15(1). doi:10.1186/s13023-020-01513-6

18. Ribeiro H, Lima VM, Waldman EA. In the COVID-19 pandemic in Brazil, do brown lives matter? *Lancet Glob Heal*. 2020;8(8):e976-e977. doi:10.1016/S2214-109X(20)30314-4

19. Topal Hançer A, Yilmaz P, Yilmaz M. New coronavirus (2019-nCoV/COVID-19) and vitamin C [Yeni koronavirüs (2019-nCoV/COVID-19) ve vitamin C]. *Turkiye Klin J Med Sci*. 2020;40(2):260-264. doi:10.5336/medsci.2020-76024

20. Horowitz RI, Freeman PR. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials. *Med Hypotheses*. 2020;143. doi:10.1016/j.mehy.2020.109851

21. Abbas AM, Kamel MM. Dietary habits in adults during quarantine in the context of COVID-19 pandemic. *Obes Med*. 2020;19. doi:10.1016/j.obmed.2020.100254

22. Vrba SM, Kirk NM, Brisse ME, Liang Y, Ly H. Development and applications of viral vectored vaccines to combat zoonotic and emerging public health threats. *Vaccines*. 2020;8(4):1-31. doi:10.3390/vaccines8040680

23. Breidenbach JD, Dube P, Ghosh S, et al. Impact of comorbidities on SARS-CoV-2 viral entry-related genes. *J Pers Med*. 2020;10(4):1-11. doi:10.3390/jpm10040146

24. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat Commun*. 2020;11(1). doi:10.1038/s41467-020-16256-y

25. Olagnier D, Farahani E, Thyrsted J, et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. *Nat Commun*. 2020;11(1). doi:10.1038/s41467-020-18764-3

26. Lei X, Dong X, Ma R, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. *Nat Commun*. 2020;11(1). doi:10.1038/s41467-020-17665-9

27. Bime C, Camp SM, Casanova N, et al. The acute respiratory distress syndrome biomarker pipeline: crippling gaps between discovery and clinical utility. *Transl Res*. 2020;226:105-115. doi:10.1016/j.trsl.2020.06.010

28. Basu S, Veeraraghavan B, Ramaiah S, Anbarasu A. Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease. *Microb Pathog*. 2020;149. doi:10.1016/j.micpath.2020.104546

29. Zhao H, To KKW, Sze K-H, et al. A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2. *Nat Commun*. 2020;11(1). doi:10.1038/s41467-020-17986-9

30. Abian O, Ortega-Alarcon D, Jimenez-Alesanco A, et al. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. *Int J Biol Macromol*. 2020;164:1693-1703. doi:10.1016/j.ijbiomac.2020.07.235

31. Sajuthi SP, DeFord P, Li Y, et al. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. *Nat Commun*. 2020;11(1). doi:10.1038/s41467-020-18781-2

32. Wu C-Y, Lin Y-S, Yang Y-H, Shu L-H, Cheng Y-C, Liu HT. GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies. *Biomed Pharmacother*. 2020;132. doi:10.1016/j.biopha.2020.110816

33. Krafcikova P, Silhan J, Nencka R, Boura E. Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin. *Nat Commun*. 2020;11(1). doi:10.1038/s41467-020-17495-9

ISSN 2515-8260 Volume 07, Issue 07, 2020

34. Wolf J, Bruno S, Eichberg M, et al. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. *npj Vaccines*. 2020;5(1). doi:10.1038/s41541-020-0204-7

35. Hu J, Jolkkonen J, Zhao C. Neurotropism of SARS-CoV-2 and its neuropathological alterations: Similarities with other coronaviruses. *Neurosci Biobehav Rev*. 2020;119:184-193. doi:10.1016/j.neubiorev.2020.10.012

36. Morsy S. NCAM protein and SARS-COV-2 surface proteins: In-silico hypothetical evidence for the immunopathogenesis of Guillain-Barré syndrome. *Med Hypotheses*. 2020;145. doi:10.1016/j.mehy.2020.110342

37. Bazmjoo A, Bagherzadeh MA, Farahmandpoor F, Raoofi R, Abdoli A. SARS-CoV-2 infection in an advanced rheumatoid arthritis patient. *APMIS*. 2020;128(12):654-656. doi:10.1111/apm.13080

38. Root-Bernstein R. Possible cross-reactivity between SARS-CoV-2 proteins, CRM197 and proteins in pneumococcal vaccines may protect against symptomatic SARS-CoV-2 disease and death. *Vaccines*. 2020;8(4):1-20. doi:10.3390/vaccines8040559

39. Gurung AB. In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors. *Gene Reports*. 2020;21. doi:10.1016/j.genrep.2020.100860

40. Karjee S, Mukherjee SK. RNAi suppressor: The hidden weapon of SARS-CoV. *J Biosci*. 2020;45(1). doi:10.1007/s12038-020-00071-0